By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sonoma Pharma (Formerly Known As Oculus Innovative Sciences, Inc.) 

1135 North McDowell Boulevard

Petaluma  California  94954  U.S.A.
Phone: 707-782-0792 Fax: 707-782-0705


Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures, and markets a family of Microcyn® Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus’ platform technology, called Microcyn, is a non-irritating proprietary oxychlorine formulation designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.

Oculus’ principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V.

Last Updated: 05-23-2007

Key Statistics

Ownership: Public

Web Site: Sonoma Pharma
Symbol: OCLS

Company News
Sonoma Pharma (OCLS) Announces Commercialization Of MicrocynAH Animal Healthcare Products In Japan 9/14/2017 10:16:39 AM
Sonoma Pharma (OCLS) Reports Financial Results For First Quarter Of Fiscal Year 2018 8/9/2017 1:39:29 PM
Sonoma Pharma (OCLS) Announces Fiscal First Quarter 2018 Financial Results And Conference Call 7/25/2017 11:42:07 AM
Sonoma Pharma (OCLS) Announces Record Quarterly Prescription Data 7/13/2017 8:08:28 AM
Sonoma Pharma (OCLS) Announces Publication Of Consensus Report Describing Celacyn's (Hypochlorous Acid) Impact On Post-Procedure Treatment And Scar Prevention 6/28/2017 9:57:35 AM
Sonoma Pharma (OCLS) Announces Two Singapore Approvals For Microcyn (Hypochlorous Acid) For The Treatment Of Atopic Dermatitis And Hypertrophic / Keloid Scars 6/20/2017 10:34:05 AM
Sonoma Pharma (OCLS) Reports Financial Results For Fourth Quarter And Fiscal Year 2017 6/5/2017 1:38:09 PM
Sonoma Pharma (OCLS) Announces Fiscal Year/Fourth Quarter 2017 Financial Results And Conference Call 6/2/2017 9:02:43 AM
Bay Area's Sonoma Pharma (OCLS) Wins FDA Clearance for Loyon Skin Descaler 3/29/2017 7:24:56 AM
Sonoma Pharma (OCLS) Receives Final $1.5 Million Payment From Sale Of Latin America Business To Invekra S.A.P.I. De C.V. 3/23/2017 11:47:17 AM